^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer

Excerpt:
Human cancer xenograft models were selected for in vivo testing on the basis of having favorable SLC44A4 expression...Antitumor activity of ASG-5ME, nab-paclitaxel, or the combination was evaluated in AG-Panc4 pancreatic xenograft models. In the AG-Panc4 model (Fig. 6D), ASG-5ME (1 mg/kg) or nab-paclitaxel (100 mg/kg) administered every 4 days for a total of 3 doses both demonstrated modest antitumor activity compared with the control, resulting in 40.3% (P = 0.0100) and 32.6% (P = 0.0384) tumor growth inhibition, respectively, on day 29. When given in combination, a significant improvement in activity was observed resulting in 72.7% (P < 0.0001) tumor growth inhibition. The combination activity was superior to single-agent ASG-5ME (P = 0.0043) or nab paclitaxel (P = 0.0009).
DOI:
10.1158/1535-7163.MCT-16-0225